{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3010","value":"9300"},{"groupId":"OG001","spread":"5520","value":"21300"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"AUC was defined as area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Isatuximab 10 mg/kg IV infusion QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 112 weeks).","id":"OG000","title":"Phase 1, Cohort 1: Isatuximab 10 mg/kg"},{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 137 weeks).","id":"OG001","title":"Phase 1, Cohort 2: Isatuximab 20 mg/kg"}],"paramType":"MEAN","populationDescription":"Analysis was performed on PK population. Here, \"Overall number of participants analyzed\" = participants with available data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 at 0 hour (pre-dose), mid-infusion (2 hours post-infusion), EOI and EOI+4-hour, Day 2 (24 hour), Day 3 (48 hour), Day 4 (72 hour) and pre-dose on Day 8 (0 hour)","title":"Phase 1: Area Under the Plasma Concentration Versus Curve Over the Dosing Interval (AUC1-week) After First Infusion of Isatuximab","type":"SECONDARY","unitOfMeasure":"micrograms*hours per milliliter"}